What Can Be Learnt about Disease Progression in Breast Cancer Dormancy from Relapse Data?

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Willis, Lisa ^a,b   Graham, Trevor A ^a,c   Alarcón, Tomás ^d   Alison, Malcolm R ^e   Tomlinson, Ian P M ^f   Page, Karen M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CENTRE DE RECERCA MATEMÀTICA   (Spain)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; FOLLOW UP; HUMAN; MATHEMATICAL MODEL; METASTASIS; MUTATION; PATHOPHYSIOLOGY;

ALGORITHMS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MARKOV CHAINS; MODELS, BIOLOGICAL; NEOPLASM MICROMETASTASIS; NEOPLASM RECURRENCE, LOCAL;

EID: 84877095341     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062320     Document Type: Article

References (39)

1. Karrison T, Ferguson D, Meier P, (1999) Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 91: 80-85.
2. Uhr JW, Pantel K, (2011) Controversies in clinical cancer dormancy. Proceedings of the National Academy of Sciences USA 108: 12396-12400.
3. Aguirre-Ghiso JA, (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7: 834-846.
4. Chambers AF, Goss PE, (2008) Putative growth characteristics of micrometastatic breast cancer. Breast Cancer Res 10: 114.
5. Demicheli R, Retsky MW, Swartzendruber DE, Bonadonna G, (1997) Proposal for a new model of breast cancer metastatic development. Ann Oncol 8: 1075-1080.
6. Meltzer A, (1990) Dormancy and breast cancer. J Surg Oncol 43: 181-188.
7. Demicheli R, Terenziani M, Bonadonna G, (1998) Estimate of tumor growth time for breast cancer local recurrences: rapid growth after wake-up? Breast Cancer Res Treat 51: 133-137.
8. Holmgren L, O'Reilly MS, Folkman J, (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1: 149-153.
9. Bouck N, Stellmach V, Hsu SC, (1996) How tumors become angiogenic. Advanced Cancer Research 69: 135-174.
10. Hanahan D, Folkman J, (1996) Patterns and emerging mechanisms of the angiogenic switch in during tumorigenesis. Cell 86: 353-364.
11. Gimbrone MA, Leapman SB, Cotran RS, Folkman J, (1972) Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136: 261-276.
12. O'Reilly MS, Holmgren L, Chen C, Folkman J, (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2: 689-962.
13. Naumov G, Bender E, Zurakowski D, Kang S, Sampson D, et al. (2006) A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 98: 316-325.
14. Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, et al. (2009) Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 69: 836-844.
15. Weinhold KJ, Goldstein LT, Wheelock EF, (1977) Tumour-dormant states established with L5178Y lymphoma cells in immunised syngeneic murine hosts. Nature 270: 59-61.
16. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, et al. (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450: 903-907.
17. Naumov GN, MacDonald IC, Chambers AF, Groom AC, (2001) Solitary cancer cells as a possible source of tumour dormancy? Semin Cancer Biol 11: 271-276.
18. Radisky DC, LaBarge MA, (2008) Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2: 511-512.
19. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
20. Meng S, Tripathy D, Frenkel E, Shete S, Naftalis E, et al. (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10: 8152-8162.
21. Retsky MW, Demicheli R, Swartzendruber D, Bame P, Wardwell R, et al. (1997) Computer simulation of a breast cancer metastasis model. Breast Cancer Res Treat 45: 193-202.
22. Willis L, Alarcón T, Elia G, Jones JL, Wright NA, et al. (2010) Breast cancer dormancy can be maintained by small numbers of micrometastases. Cancer Res 70: 4310-4317.
23. Armitage P, Doll R, (1954) The age distribution of cancer and a multistage theory of carcinogenesis. British Journal of Cancer 8: 1-12.
24. Hornsby C, Page KM, Tomlinson IPM, (2007) What can we learn from the population incidence of cancer? armitage and doll revisited. The Lancet Oncology 8: 1030-1038.
25. Bos SD, Mensink HJ, (1996) Spontaneous caval tumor thrombus necrosis and regression of pulmonary lesions in renal cell cancer. Scand J Urol Nephrol 30: 489-492.
26. Ogihara Y, Takeda K, Yanagawa T, Hirasawa Y, (1994) Spontaneous regression of lung metastases from osteosarcoma. Cancer 74: 2798-2803.
27. Rayson D, Pitot HC, Kvols LK, (1997) Regression of metastatic carcinoid tumor after valvular surgery for carcinoid heart disease. Cancer 79: 605-611.
28. Retsky MW, Demicheli R, Hrushesky WJM, Baum M, Gukas ID, (2008) Dormancy and surgery- driven escape from dormancy help explain some clinical features of breast cancer. APMIS 116: 730-741.
29. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, et al. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563.
30. Early-Breast-Cancer-Trialists'-Collaborative-Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365: 1687-1717.
31. Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA, (2004) Ten-year outcomes in a population- based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers with-out adjuvant systemic therapies. J Clin Oncol 22: 1630-1637.
32. Arizona software (2008) GraphClick, Version 3.0.
33. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, et al. (2007) Proposal for stan- dardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25: 2127-2131.
34. Demicheli R, (2001) Tumour dormancy: findings and hypotheses from clinical research on breast cancer. Semin Cancer Biol 11: 297-306.
35. Yin W, Di G, Zhou L, Lu J, Liu G, et al. (2009) Time-varying pattern of recurrence risk for Chinese breast cancer patients. Breast Cancer Res Treat 114: 527-535.
36. Saphner T, Tormey DC, Gray R, (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14: 2738-2746.
37. Folkman J, (2006) Angiogenesis. Annu Rev Med 57: 1-18.
38. Nussenbaum F, Herman IM, (2010) Tumor angiogenesis: insights and innovations. J Oncol 2010: 132641.
39. Paterlini-Brechot P, Benali NL, (2007) Circulating tumor cells (CTC) detection: Clinical impact and future directions. Cancer Letters 253: 180-204.